All In Biotech

Drug Trial Radar · NCT06281470

The Safety and Tolerability of WS016 in Healthy Chinese Volunteers

The First-in-Human, Single-Center, Randomized, Double-Blind, Placebo-Controlled,Single- and Multiple- Ascending Dose Study to Evaluate the Safety and Tolerability of WS016 in Healthy Chinese Volunteers

Last checked: Nov 19, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Feb 13, 2023

Primary completion

Jun 15, 2023

Study completion Jun 15, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinic trial evaluates the safety and tolerability of single- and multiple- ascending doses of WS016 in healthy adult participants. There will be about 64 participants,48 active and 16 placebo.

Conditions

  • Hyperkalemia

Interventions

  • WS016 Single Dose(6g)Drug

    WS016 6g, to be administered orally as a single dose.

  • WS016 Single Dose(12g)Drug

    WS016 12g, to be administered orally as a single dose.

  • WS016 Single Dose(24g)Drug

    WS016 24g, to be administered orally as a single dose.

  • WS016 Single Dose(36g)Drug

    WS016 36g, to be administered orally as a single dose.

  • WS016 Single Dose(48g)Drug

    WS016 48g, to be administered orally as a single dose.

  • SAD matching placeboDrug

    Matching placebo, to be administered orally as a single dose.

  • WS016 Multiple Dose(12g)Drug

    WS016 12g, to be administered orally once daily for a consecutive period of 7 days.

  • WS016 Multiple Dose(24g)Drug

    WS016 24g, to be administered orally once daily for a consecutive period of 7 days.

  • WS016 Multiple Dose(48g)Drug

    WS016 48g, to be administered orally once daily for a consecutive period of 7 days.

  • MAD matching placeboDrug

    Matching placebo, to be administered orally once daily for a consecutive period of 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single- and multiple- ascending doseTime frame: up to Day 17

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Xiaoshan Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.